Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.
BACKGROUND
Targeted therapy has significantly prolonged the survival of patients with advanced renal cell carcinoma (RCC). As first-line treatment, sunitinib, temsirolimus and bevacizumab plus IFN-alpha are demonstrated to prolong progression-free survival and/or overall survival. As second-line treatment, sorafenib was active mainly for patients in whom cytokine therapy failed. Recently, second-line treatment with everolimus has been shown to benefit patients progressing through tyrosine kinase inhibitors. Meanwhile, FDA has just approved pazopanib for the treatment of patients with advanced RCC. Various toxicities were associated with these agents. These toxicities were generally well tolerated. However, a high frequency of severe skin and bone marrow toxicities has been reported in Asian countries.


METHODS
We have reviewed the literature of current targeted therapeutic agents and hand-foot skin reaction (HFSR) in advanced RCC available in MEDLINE and meeting reports of ASCO, ECCO-ESMO and the 2009 Genitourinary Cancers Symposium.


RESULTS
Readers will know of the efficacy and safety, including HFSR, of current targeted therapy.


CONCLUSIONS
Careful monitoring and appropriate management of the toxicities, especially HFSR, are needed.
Yang
Chih-Hsun
CH
Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Department of Dermatology, Taoyuan, Taiwan.
Chuang
Cheng-Keng
CK
Hsieh
Jia-Juan
JJ
Chang
John Wen-Cheng
JW
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D016503:Drug Delivery Systems / Q000379:methods*; D005528:Foot / Q000473:pathology; D006225:Hand / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
D000970:Antineoplastic Agents